help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KING, T. E.
Right arrow Articles by CHERNIACK, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KING, T. E., JR.
Right arrow Articles by CHERNIACK, R. M.
Am. J. Respir. Crit. Care Med., Volume 164, Number 7, October 2001, 1171-1181

Predicting Survival in Idiopathic Pulmonary Fibrosis
Scoring System and Survival Model

TALMADGE E. KING JR., JANET A. TOOZE, MARVIN I. SCHWARZ, KEVIN R. BROWN, and REUBEN M. CHERNIACK

Departments of Medicine and Divisions of Pulmonary and Critical Care Medicine, San Francisco General Hospital, and the University of California, San Francisco, San Francisco, California; National Jewish Medical and Research Center, and the University of Colorado Health Sciences Center, Denver, Colorado




    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Our purpose was to identify clinical, radiological and physiological (CRP) determinants of survival and to develop a CRP scoring system that predicts survival in newly diagnosed cases of idiopathic pulmonary fibrosis (IPF). The study population consisted of 238 patients with biopsy confirmed usual interstitial pneumonia. For each patient, clinical manifestations, chest radiographs, and pulmonary physiology were prospectively assessed. We used Cox proportional-hazards models to assess the effect of these parameters on survival. The effects of age and smoking were included in the analysis. Survival was related to age, smoking status (longer in current smokers), clubbing, the extent of interstitial opacities and presence of pulmonary hypertension on the chest radiograph, reduced lung volume, and abnormal gas exchange during maximal exercise. A mathematical CRP score for predicting survival was derived from these parameters. We showed that this CRP score correlated with the extent and severity of the important histopathologic features of IPF, i.e., fibrosis, cellularity, the granulation/connective tissue deposition, and the total pathologic derangement. Using these models, clinicians are in a better position to provide prognostic information to patients with IPF and to improve the selection of the most appropriate patients for lung transplantation or other standard or novel therapeutic interventions.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Keywords: idiopathic pulmonary fibrosis; usual interstitial pneumonia; prospective studies; pulmonary function tests; smoking physiopathology; survival rate

Death occurs within 5 yr of diagnosis in the majority of patients with idiopathic pulmonary fibrosis (IPF). Physicians caring for such patients are frequently required to make complex and difficult decisions regarding whether or not to start, intensify, or stop treatment; or when to recommend referral of the patient for lung transplantation, which has been shown to lead to improved lung function and confers a survival benefit in these patients (1). These decisions would be made easier if accurate and objective measurements of the patient's current clinical status and risk of progression to death were available. Reported prognostic indicators of survival in patients with IPF have been inconsistent in different studies. This is because most studies have been based on a relatively small number of patients, and they have included patients with other conditions such as connective tissue disorders (2). Most importantly, in the majority of reports, the diagnosis of usual interstitial pneumonia (UIP), the histopathologic subset of idiopathic interstitial pneumonia found in IPF, was frequently not confirmed by assessment of surgical lung biopsy (5). This is an important distinction since response to treatment and outcome varies among the different histologic subsets of idiopathic interstitial pneumonia.

We previously described a composite clinical-radiologic-physiologic (CRP) scoring system to evaluate the clinical status of patients with IPF (8). This CRP scoring system was recommended as a quantitative tool for the serial assessment of clinical impairment in patients with IPF (8, 9). However, the value of this CRP scoring system for predicting survival was not assessed. In the present study, we prospectively analyzed the clinical course of 238 patients with IPF. Our goal was to determine whether the risk of death caused by respiratory failure could be predicted based on clinical, radiologic, and physiologic parameters obtained during initial entry into the study. Based upon the features that were shown to be the best determinants of survival, we have devised a scoring system that predicts survival in patients with IPF.


    METHODS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Study Population

The study group consisted of 238 patients with IPF prospectively enrolled into a Specialized Center of Research Study at the National Jewish Medical and Research Center (NJC) between 1982 and 1996 (Table 1). The diagnosis of IPF was made based on established clinical and histologic criteria (5). Patients were excluded from the study if there was clinical evidence of a connective tissue disease, left ventricular failure, an occupational or environmental exposure that may result in interstitial lung disease, or a history of ingestion of a drug or an agent known to cause pulmonary fibrosis. At the initial visit to the NJC, all subjects underwent clinical, radiographic, and physiologic assessment before lung biopsy. Informed consent was obtained from each patient, and the Institutional Human Subject Review Committee approved the protocol.

                              
View this table:
[in this window]
[in a new window]
 

TABLE 1

 DEMOGRAPHIC CHARACTERISTICS OF STUDY SUBJECTS STRATIFIED BY SMOKING STATUS*

The study population consisted of 152 men and 86 women, with a mean age of 61.4 yr (range, 27 to 79 yr), and 211 (89%) were Caucasian (Table 1). Subjects were designated as current smokers if they had smoked cigarettes regularly within the previous year (n = 33), former smokers if they had not smoked cigarettes in the previous year but had smoked in the past (n = 121), and never smokers (n = 84). It can be seen in Table 1 that there are significant differences in age and sex among the smoking groups: current smokers were younger than never or former smokers; and among never smokers, the male/female ratio was 0.65:1.

Clinical Assessment

A modified American Thoracic Society (ATS) questionnaire was used to collect demographic and medical information (8). The type and amount of exertion required to precipitate shortness of breath was assessed using a previously described dyspnea scale (8). The duration of illness was defined as the time from the onset of the disease, as determined from either the patient's recollection of the first appearance of cough throughout the day or of dyspnea walking up inclines. The median duration of illness was 2 yr (Table 1). There was no significant difference in duration of illness among the smoking groups. The median length of follow-up was 20 mo, with a maximum of 14.8 yr.

After entry into the study, most patients received treatment for their illness with prednisone alone, cyclophosphamide alone, or both in combination. The combination was usually given to patients with more severe disease that progressed during follow-up. Treatment appeared to have little or no impact on survival compared with no treatment (data not shown). Survival was assessed through July 31, 1998. Deaths were identified from follow-up with the patient's family or physician or by search of the national death registry. The cause of death was obtained by review of the hospital discharge information (and, when available, the autopsy reports) on all deaths. There were 155 deaths during the study period (65%): 125 died secondary to IPF, 19 died because of other causes. In 11 patients, in whom the cause of death was unknown, it was considered to be due to IPF. One hundred five patients (44%) were censored, including 79 who were alive at time of the analysis, 13 who had undergone lung transplantation, 12 who died of a cause other than IPF, and one who was lost to follow-up.

Radiographic Assessment

Assessment of the chest radiograph was carried out as previously described (12). The severity and profusion of parenchymal interstitial opacities, the extent of honeycomb changes, and the presence or absence of evidence of pulmonary hypertension were graded on standard posteroanterior chest radiographs.

Physiologic Assessment

Physiologic assessment included measurement of thoracic gas volume (Vtg) and TLC; FVC and FEV1; the volume-pressure relationship of the lungs, and the single-breath diffusing capacity for carbon monoxide (DLCO). These methods have been previously described (10).

In 205 patients, the volume-pressure relationship of the lungs was measured in a body plethysmograph as previously described (15). The coefficient of elastic retraction was calculated by dividing maximal static transpulmonary pressure by TLC. The normal value in our laboratory is 3 to 8 cm H2O/L. The volume-pressure data were also subjected to an exponential curve fit where volume is expressed as a percentage of observed TLC, and the exponential K, a constant that is proportional to the total incremental compliance, was derived from the equation: V = A - Be-Kp, where V is the volume at a given pressure (p), A is the maximal theoretical volume at infinite pressure, and B is A minus the intercept of the fitted exponential on the volume axis (17).

Gas Exchange at Rest and during Exercise

Respiratory frequency, tidal volume, expired gas concentrations, heart rate, and blood pressure and arterial blood gas tensions were determined at rest and while exercising on an electrically braked bicycle ergometer during incremental work loads (maximal exercise testing), and during steady-state exercise at 50% of the maximum work load achieved during the incremental exercise testing. Arterial blood gases were determined with blood electrodes. The AaPO2 was calculated from the simplified alveolar air equation (18).

Because approximately half of the patients required supplemental oxygen during exercise, the steady-state exercise PaO2 and AaPO2 were corrected for FIO2, using the equation:
P<SUB>O<SUB>2</SUB></SUB>(corr) = (Pa<SUB>O<SUB>2</SUB></SUB>/F<SC>i</SC><SUB>O<SUB>2</SUB></SUB>) × 21 and <SC>a</SC>aP<SUB>O<SUB>2</SUB></SUB>(corr) = <SC>a</SC>aP<SUB>O<SUB>2</SUB></SUB>/F<SC>i</SC><SUB>O<SUB>2</SUB></SUB>) × 21.

Dead space to tidal volume ratio (VD/VT) was calculated using the Bohr equation and corrected for the additional mechanical dead space imposed by the experimental apparatus: VD = [(PaCO2 - PECO2)/PaCO2] × VT minus (mechanical dead space of apparatus).

Oxygen consumption (VO2) and maximal work load achieved were expressed as percent of predicted reference values obtained from the age- and sex-adjusted equations of Jones and Campbell (19).

Pathologic Assessment

All patients underwent open thoracotomy or video-assisted thoracoscopic lung biopsy. In each patient, tissue was obtained from at least two sites, the upper and lower lobes of the same lung (when technically feasible). Findings consistent with usual interstitial pneumonia (UIP) were present in the patients with IPF (5). In light of the recent change in the definition of the pathologic features of the idiopathic interstitial pneumonia all of the biopsies were reviewed (5) and those patients who demonstrated the histopathologic patterns of desquamative interstitial pneumonia (DIP), nonspecific interstitial pneumonia (NSIP), respiratory bronchiolitis associated with interstitial lung disease (RBILD), lymphoid interstitial pneumonia (LIP), diffuse alveolar damage, pulmonary Langerhans' cell granulomatosis, hypersensitivity pneumonitis, sarcoidosis, or idiopathic bronchiolitis obliterans organizing pneumonia (idiopathic BOOP) were excluded from the study. For each patient, a semiquantitative assessment of inflammatory/exudative changes, fibrotic/reparative changes, and airway alterations, in addition to an overall assessment of cellularity and fibrosis was performed as previously described (20, 21).

Statistical Analysis

The median and interquartile ranges (IQR) were calculated for each explanatory variable originally considered for the CRP model. Differences among smoking groups were assessed using the Kruskal-Wallis test, followed by Wilcoxon's pairwise rank-sum tests if the Kruskall-Wallis test was significant. The Kaplan-Meier method (22) was used to produce estimates and plots for the patient cohort as a whole, and stratified by sex, age, and smoking status. Survival time was calculated as the number of months from the patients' initial visits until their death or time of censoring. Patients were censored if they: (1) were still alive at the last contact, (2) had received a single lung transplant (n = 11), double lung transplant (n = 1), or a heart and lung transplant (n = 1) or, (3) died from a cause other than IPF. When the cause of death was unknown (n = 11), it was considered due to IPF. The log-rank test was used to compare survival time between groups. The final score met the assumption of proportional hazards assumed by the Cox model.

Univariate and age- and smoking-adjusted analysis. The effect of each potential explanatory variable on the hazard function was considered in a univariate analysis using Cox proportional hazards regression. Because the univariate analysis indicated that age and smoking status (never, former, or current smoker) were predictive of survival, Cox proportional hazards regression was used to model the effect of the explanatory variables on the hazard function, adjusting for the effects of age and smoking status. Hazard ratios, the relative amount of risk associated with a specified increase in the explanatory variable, are reported for the age- and smoking-adjusted analyses.

Influential points, outliers that had a large effect on the fit of the regression model, were identified through exploration of plots and by using likelihood displacement (LD) and lmax statistics (23). Points that were considered influential observations (n = 16) were excluded from the univariate analysis and subsequent analyses. Although this represents 8% of the patients without missing data, according to the lmax statistic these patients accounted for 85% of the influence on the parameter estimates (data not shown).

Multivariable analysis. Variables with a p value of 0.25 or lower in the age- and smoking-adjusted analyses were considered for inclusion in the multivariable model. In order to avoid multicollinearity, Pearson's correlation was performed to detect variables that were highly correlated. If the Pearson's correlation coefficient was 0.60 or greater, the variable that was most significant in the age- and smoking-adjusted analysis was entered into the multivariable model. A forward elimination process was used to develop a preliminary multivariable model. All measured variables (including those that were eliminated because of high correlation with other variables in the model) were substituted into this preliminary multivariable model in order to develop a final model. Multivariable influential points were identified through LD and lmax statistics (24), and eliminated if necessary. Two models were developed using this process: one with complete data, and one for patients who did not complete exercise and lung mechanics testing.

Development of a clinical-radiologic-physiologic (CRP) scoring system. To develop a reproducible, quantifiable means for assessing the clinical status and potential prognosis of patients with IPF we computed a composite CRP scoring system using the models derived from the multivariable analysis. Values for each variable in a model were graded into two to nine levels of severity, based on the range of the data for each parameter. These categories were weighted so that all variables had equivalent minimum and maximum scores. The model was rerun with the grouped variables, and Akaike's Information Criteria (AIC) (24) was used to compare the model with the categorical variables to the model with the continuous variables. A final score, with a maximum of 100 points, based on the p value and relative hazard ratio of each categorized variable, was developed. The total score was tested for nonproportional hazards.

A second abbreviated CRP scoring system was developed in an analogous manner to that described above for the complete model; however, this abbreviated model did not include exercise or lung mechanics testing. This analysis led to an abbreviated scoring system that contained a subset of the score developed in the complete model. For this reason, the scoring system derived from the abbreviated model was compared with the scoring system derived from the complete model (using AIC). It was determined that the scoring system derived from the complete CRP model was superior to the abbreviated CRP scoring system.

Scores from the two models were compared using AIC on the subset of patients (n = 148) in whom data were available to derive scores for both models. Because the abbreviated CRP model was a subset of the first model, a likelihood ratio test was used to compare the two models. Pearson's correlation was used to examine the relationship between the newly developed complete and abbreviated CRP scores, the original published CRP score, and the semiquantitative evaluation of the lung histopathology. In addition, a Cox regression model was used to determine if absence of lung mechanics or exercise testing was significantly related to the risk of death.

All data analyses were performed using the SAS statistical package (SAS Institute Inc., Cary, NC). Unless otherwise noted, all tests were two-sided and performed at the 0.05 significance level.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

The clinical, radiographic, and physiologic measurements, obtained at the time of the initial visit are shown in Tables 2 and 3, for the group as a whole, and relative to smoking status.

                              
View this table:
[in this window]
[in a new window]
 

TABLE 2

 CLINICAL, RADIOGRAPHIC, AND PHYSIOLOGIC CHARACTERISTICS OF STUDY PARTICIPANTS STRATIFIED BY SMOKING STATUS

                              
View this table:
[in this window]
[in a new window]
 

TABLE 3

 GAS EXCHANGE AT REST AND DURING EXERCISE OF STUDY PARTICIPANTS STRATIFIED BY SMOKING STATUS

Clinical Findings

The dyspnea grade was similar for all smoking classes. Moderate or many crackles were present in 192 subjects (81%) and finger clubbing was seen in 65 (27%) subjects. Never smokers had significantly less frequent finger clubbing than did former or current smokers. There was a higher proportion of current smokers with none or few crackles heard on chest examination than never and former smokers.

Radiographic Findings

The profusion of parenchymal interstitial opacities on the chest radiograph were similar among the subjects stratified by smoking status, with former smokers exhibiting the greatest amount of profusion. The extent of honeycombing was significantly greater in the former smokers than in the never and current smokers. The number of patients with evidence of pulmonary hypertension on the chest radiograph was significantly less in never smokers than in former or current smokers.

Pulmonary Function

Lung volumes were significantly lower among never smokers than among former (SVC) or current (SVC, Vtg, and TLC) smokers. Residual volume (RV) was significantly higher in never smokers than in former smokers. In addition, former smokers had significantly lower SVC, Vtg, RV, and TLC than did current smokers.

In never smokers, the FVC and FEV1 were significantly lower and the FEV1/FVC ratio was significantly higher than in former smokers. Among current smokers, the FVC and FEV1 were significantly higher and FEV1/FVC ratio was significantly lower when compared with never and former smokers.

Volume-Pressure Relationship

The median coefficient of elastic retraction was significantly higher in never and former smokers than in current smokers, the median for the latter was in the normal range (i.e., 3 to 8 cm H2O/l). In addition, there was a significant difference in calculated "K values" (natural log) with current smokers having higher values than never and former smokers.

Resting Gas Exchange

The diffusing capacity was reduced in all groups (Table 3). Among current smokers, the DLCO/VA was lower than in never and former smokers and was lower in former smokers than in never smokers.

The median respiratory rate at rest was increased; however, there were no significant differences among the three groups. The VD/VT was increased in all groups. Among former smokers, the resting PaO2 was lower (p = NS for both comparisons) and, the AaPO2 was higher compared with never (p < 0.05) and current smokers (p = NS). O2 saturation was the same in all groups. The median VD/VT for the entire study group was abnormally elevated but was similar among the three subgroups.

Response to Exercise

The exercise physiology is summarized in Table 3. As a group, the patients demonstrated a limitation in exercise tolerance with a decreased maximal work load (median, 50.4% expressed as percentage of predicted), elevated VD/VT, and abnormal gas exchange (decreased PaO2 and elevated AaPO2). There were several significant differences during maximal exercise testing among the three groups: (1) never smokers were able to carry out exercise at a significantly lower work load (watts achieved) than were current and former smokers; however, the groups were similar in maximal work load achieved as a percentage of the predicted; (2) the respiratory rate was higher and tidal volume (VT) was lower in never smokers when compared with former and current smokers; (3) the PaO2 and the AaPO2 were significantly worse in former smokers than in never or current smokers. As expected, these differences persisted during steady-state exercise testing.

Survival Analysis

The Kaplan-Meier plot of survival probability from the reported time of onset of disease and from the initial visit at NJC for all patients can be seen in Figure 1.



View larger version (9K):
[in this window]
[in a new window]
 
Figure 1.   Kaplan-Meier plot of survival probability from the time of the onset of symptoms (median survival was 80.8 mo; 95% CI: 65.5-89.3) compared with the time from initial visit (median survival was 35.2 mo; 95% CI: 23.2-48.5) (n = 238).

There was no difference in median survival (p = 0.15) between men (30.0 mo, 95% CI: 19.1-44.3) and women (39.3 mo, 95% CI: 27.2-77.8) (Figure 2).



View larger version (9K):
[in this window]
[in a new window]
 
Figure 2.   Kaplan-Meier plot of survival probability from the time of the initial visit stratified by sex (Female: n = 86, Male: n = 152).

The effect of age at the time of the initial visit on survival time is shown in Figure 3. There was a significant difference in survival among the age groups (p < 0.0001). The effect of smoking status on survival is illustrated in Figure 4.



View larger version (13K):
[in this window]
[in a new window]
 
Figure 3.   Kaplan-Meier plot of survival probability from the time of the initial visit stratified by age group (younger than 50 yr, n = 36; 50-60 yr, n = 48; 60-70 yr, n = 108; older than 70 yr, n = 46). The median survival time was: younger than 50 yr of age, 116.4 mo; 50-60 yr of age, 62.8 mo; 60 to 70 yr of age, 27.2 mo; 70 yr of age or older, 14.6 mo.



View larger version (11K):
[in this window]
[in a new window]
 
Figure 4.   Kaplan-Meier plot of survival probability from the time of the initial visit stratified by smoking group (Current: n = 33, Former: n = 121, Never: n = 84 ). There was a significant difference (p = 0.0003) between the three smoking groups. The median survival time in the current smokers was 116.4 mo and it was 25.3 mo in former smokers and 27.2 mo in never smokers.

Age and Smoking-adjusted Analysis

The hazard ratios of the variables tested individually, and when adjusted for age and smoking are presented in Table 4. The degree of dyspnea; presence of finger clubbing; the extent of profusion and honeycombing, as well as evidence of pulmonary hypertension on chest radiograph; the severity of impairment of lung volume, spirometry, lung mechanics, DLCO, and gas exchange while at rest and during exercise were all significant (p < 0.05) predictors of survival.

                              
View this table:
[in this window]
[in a new window]
 

TABLE 4

 HAZARD RATIOS FOR AGE AND SMOKING-ADJUSTED ANALYSES FOR VARIABLES CONSIDERED FOR MULTIVARIABLE MODEL

Multivariable Analysis

Multivariable analysis was used to identify those manifestations that were significantly related to survival while controlling for the other factors in the model. The complete model was developed from the subset of patients (n = 183) in whom there were data for all variables. The variables considered in the complete model are shown in Table 4. Many of the variables considered for inclusion in the multivariable analysis were highly correlated with each other (r >=  0.60). Thus, in order to avoid multicollinearity, the variable that was most significant in the age- and smoking-adjusted univariate analysis was used as a surrogate for the correlated variables. Each variable was entered into the multivariable complete model in the following order in descending order of significance: PaO2, TLC, FEV1, Work, Rest O2 sat, VD/VT, and DLCO/VA (Table 5). This analysis resulted in the complete model that included: age, smoking history; clubbing; extent of profusion of interstitial opacities, and presence or absence of pulmonary hypertension on the chest radiograph; % predicted TLC; and PaO2 at the end of maximal exercise (Table 6).

                              
View this table:
[in this window]
[in a new window]
 

TABLE 5

 CORRELATIONS OF VARIABLES CONSIDERED FOR INCLUSION IN MULTIVARIABLE MODEL (r >=  0.60)

                              
View this table:
[in this window]
[in a new window]
 

TABLE 6

 CLINICAL-RADIOGRAPHIC-PHYSIOLOGIC SCORING SYSTEM FOR PREDICTING SURVIVAL TIME IN PATIENTS WITH IPF

Because lung mechanics and exercise testing are not routinely performed in many medical centers, we developed a second abbreviated model that excluded the pulmonary mechanics and exercise data in 228 patients who had all other parameters assessed. This analysis resulted in an abbreviated model with identical variables, with the exclusion of PaO2 during maximal exercise. The levels of severity of disturbance of each variable used in the abbreviated model and the corresponding assigned points are shown in Table 6. In both models the score rises as the patient ages, develops clubbing, worsening profusion of opacities or evidence of pulmonary hypertension on chest radiograph, or physiologic impairment worsens. The maximal possible CRP score being 100 points in the complete model, and 89.5 points in the abbreviated model.

Comparison of Accuracy of New and Original CRP Scores to Predict Survival

We were able to compare the ability to predict survival time of the previously reported CRP score (8) with the complete CRP score in 82 patients, and with the abbreviated score in 91 patients. The variables in the original CRP score included: rest AaPO2; calculation of an exercise score; lung function (FVC, FEV1, and Vtg); dyspnea; chest radiographic extent of interstitial opacities; honeycomb change and presence or absence of pulmonary hypertension; and DLCO/VA. Although both the complete and the abbreviated model correlated significantly with the original CRP score (r = 0.48, p < 0.0001; and r = 0.46, p < 0.0001; respectively), AIC indicated that the complete CRP model was superior to the abbreviated model in predicting survival, and that both were superior to the original CRP score. In addition, the likelihood ratio test showed that the complete CRP scoring system was superior (p = 0.03) to both the abbreviated and our previously reported CRP scoring system.

Correlation of New and Original CRP Scores and Histopathology Data

We have recently demonstrated that analysis and quantification of the specific histopathologic features found in UIP is useful in predicting the prognosis of patients with IPF (25). Specifically, survival was longer in subjects with lesser degrees of granulation/connective tissue deposition (fibroblastic foci) (25). We sought to determine whether the complete or original CRP scoring systems could be used as an indication of the severity of the underlying histopathology. We assessed the relationship between the pathologic alterations using a semi-quantitative scoring system (17, 21) and the CRP scores, in those patients (n = 77) in whom the semiquantitative analysis of pathology was performed. As can be seen in Table 7, there was no significant relationship between the original CRP score and any pathologic feature. On the other hand, there was a significant relationship between the complete CRP scoring system and the fibrosis factor (r = 0.25, p = 0.046), the cellularity factor (r = 0.25, p = 0.045), the granulation/connective tissue factor (r = 0.43, p < 0.001), and the total pathology score (r = 0.37, p = 0.003). The abbreviated CRP scoring system correlated with the fibrosis factor (r = 0.26, p = 0.021), the granulation/connective tissue factor (r = 0.49, p < 0.001), and the total pathology score (r = 0.38, p < 0.001).

                              
View this table:
[in this window]
[in a new window]
 

TABLE 7

 PEARSON'S CORRELATION COEFFICIENTS OF CRP SCORES AND PATHOLOGY*


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

In the present study, we prospectively evaluated 238 patients with biopsy-proven UIP. Our purpose was to define the clinical, radiologic, and physiologic determinants of survival. We sought to devise a new clinical-radiologic-physiologic scoring system, based on these determinants, that could predict survival in newly diagnosed cases of IPF.

In agreement with other studies, our study confirms that IPF is predominantly a disease of elderly men, with a mean age at presentation of 61 yr and a male-to-female ratio of 1.77:1. Survival is markedly reduced, the median survival being 81 mo from the estimated onset of the illness and 35 mo from the time of the initial visit (Figure 1). We found that survival was significantly related to age at presentation, presence or absence of finger clubbing, cigarette smoking history, profusion of interstitial opacities and evidence of pulmonary hypertension on the chest radiograph, reduced lung volume, and gas exchange abnormalities with exercise. In contradistinction to previous reports (26), we found that dyspnea, sex, and diffusing capacity were not independent predictors of survival in the multivariate analyses.

Using the identified independent determinants of survival, we developed a mathematical clinical-radiologic-physiologic scoring system for prediction of survival time in patients with IPF. This new complete CRP score included the following parameters: age, smoking history; clubbing; extent of profusion of interstitial opacities and presence or absence of pulmonary hypertension on the chest radiograph; % predicted TLC; and PaO2 at the end of maximal exercise. Further, we demonstrated that this complete CRP score correlated with the extent and severity of the important histopathologic features of IPF: fibrosis, cellularity, the granulation/connective tissue, and the total pathologic derangement.

Cigarette Smoking Influences Survival in IPF

Our data show that survival is extended in patients with IPF who are cigarette smokers at the time of their initial evaluation (25) when compared with former smokers or never smokers. Several studies have shown a high percentage of ever smokers among persons with IPF (3, 9, 26) and that cigarette smoking is an independent risk factor for the development of IPF (29). However, being a cigarette smoker has only recently been shown to be associated with improved survival in this disease (25). Of interest, in a case control study of IPF (29), when current and former smokers were analyzed separately, the hazard ratio for developing IPF was not increased in current smokers.

The explanations for the longer survival in patients with IPF who are smoking cigarettes at the time of their initial presentation are unclear. It is possible that smokers seek attention earlier because of smoking-related symptoms or, conversely, they may be better able to tolerate their symptoms and seek attention when their disease has progressed enough to cause cessation of smoking. This study has demonstrated differences in several features between current smokers and former smokers or never smokers. Current smokers compared with never smokers had: (1) less crackles on chest examination and more frequent digital clubbing; (2) more evidence of pulmonary hypertension on chest radiograph; (3) less reduction in lung volumes and FEV1; (4) a lower coefficient of elastic retraction; as well as (5) the capability of higher exercise work loads, which was associated with better gas exchange. These data are consistent with our previous demonstration of differences in pulmonary function (17), specifically a shift upward and to the left of the volume-pressure curve of the lungs in smokers with IPF (30). It is possible that the higher lung volume and lower FEV1/ FVC ratio and lower coefficient of elastic retraction in current smokers reflect concomitant emphysema. The effect of these two disease processes may markedly influence lung function and alter the prognosis of patients with IPF.

Interestingly, cigarette smoking alters the histopathologic appearance of IPF, and this may partially explain the longer survival in current smokers (25). Current smokers showed lesser degrees of overall cellularity but greater extent and severity of alveolar space cellularity-likely reflecting increased inflammation secondary to ongoing accumulation of macrophages as a result of smoking. The fibrotic changes are similar among the smoking groups. However, the extent and severity of granulation/connective tissue scores was less in current smokers. There are no differences in the pathology factor scores between never smokers and former smokers. Limited data exist regarding the effect of cigarette smoke on fibroblast function; however, our findings are interesting in light of data that suggest that cigarette smoke inhibits lung fibroblast proliferation as well as chemotaxis, and may impair lung repair after lung injury (31).

Development of a Clinical-Radiologic-Physiologic Scoring System to Predict Survival

In our previous study (8), we proposed a CRP scoring system in which points were arbitrarily assigned to various features thought to be useful in monitoring the course of IPF. In descending order of magnitude these were gas exchange at rest and during exercise; ventilatory function; dyspnea; chest radiographic extent of interstitial opacities, honeycomb change and presence or absence of pulmonary hypertension; and diffusing capacity. Despite the arbitrary apportionment of points, the original scoring system reflected the extent and severity of the disease process, as judged by a rough assessment of histopathologic changes. No attempt was made to correlate the original CRP score with survival.

In the present study, we used hierarchical multivariable analysis of clinical, radiologic, and extensive physiologic variables to develop a model that would allow clinicians to make more precise prognostic estimations about patients with IPF. The complete CRP scoring system was derived in 183 patients with IPF, and based on: age, smoking history, finger clubbing, the extent of profusion of interstitial opacities and evidence of pulmonary hypertension on the chest radiograph, the percent predicted TLC, and the PaO2 during maximal exercise. A second abbreviated CRP scoring system, determined in 228 patients with data that excluded the PaO2 during maximal exercise, was shown to be inferior by AIC analysis and a likelihood ratio test in predicting survival. Both new scoring systems were better at predicting survival time compared with our original CRP score. The predicted survival curves for patients with a given CRP score using the complete model or the abbreviated model are shown in Figures 5 and 6.



View larger version (17K):
[in this window]
[in a new window]
 
Figure 5.   Predicted survival curves for patients with a given CRP score using the complete model. We used the data generated to predict survival curves for patients with IPF and a CRP score at 10-point intervals as shown. For example, the calculated 5-yr survival at CRP scores of 20, 40, 60, and 80 were 89%, 53%, 4%, and < 1%, respectively.



View larger version (18K):
[in this window]
[in a new window]
 
Figure 6.   Predicted survival curves for patients with a given CRP score using the abbreviated model. We used the data generated to predict survival curves for patients with IPF and a CRP score at 10- point intervals as shown. For example, the calculated 5-yr survival at CRP scores of 20, 40, 60, and 80 were 85%, 41%, 1%, and < 1%, respectively.

Comparison of the Components of the New and the Original CRP Scores

It is of interest to compare the clinical, radiologic, and physiologic features that made up the previous CRP score with those of the newly derived scoring system.

Clinical features. In the original CRP score, dyspnea was assigned a significant proportion of the maximum score (20%) (8). The severity of dyspnea was a significant factor in predicting survival in the univariate analysis, but it was not an independent predictor in the multivariate analysis. Neither age nor smoking status was considered in the original model. However, the new data show both to be highly significant factors in survival in IPF, age composing as much as 25.6% of the score, and there was a difference in survival times based on smoking status.

Radiologic features. The radiographic features (profusion of interstitial opacities, honeycomb change, and presence or absence of pulmonary hypertension) were assigned only 10% of the previous maximum total score. This assignment was based on the view that although profusion of lung opacities may be quantified visually, using a modification of the ILO criteria for pneumoconiosis (8), the technique was time-consuming, and had not been proven to be clinically useful (32). The present study has shown that profusion of lung opacities and the presence or absence of pulmonary hypertension deserve considerably more weight, i.e., 28.6% of the maximum in predicting survival. Unfortunately, HRCT scans were not obtained in the early years of this study; therefore, they were not included in the present analysis. However, given current understanding of the superiority of HRCT over the chest radiograph for assessing the changes in IPF, it is likely that the addition of a quantitative assessment of HRCT scans to both current models would result in a superior scoring system.

Physiologic features. The original CRP scoring system allotted 25% of the maximum score to FVC, FEV1, and Vtg. Many of these parameters were excluded from the current model because of their interdependence with other parameters (see Table 4). The complete model assigns as much as 11% for TLC in its calculation. Gas exchange alterations were weighed heavily in the original CRP score, i.e., 45% of the maximum of points, including as much as 5% for the DLco/VA, 10% for the resting AaPO2, and 30% for measures of exercise gas exchange. Resting gas exchange was not important in the current models; however, exercise PaO2 was significantly predictive of survival and accounted for as much as 10.5% of the maximum score in the complete model.

Finally, there are several possible limitations of this study. First, all patients were required to have a surgical lung biopsy; therefore, the study did not include patients who were too ill or considered at high risk for anesthesia or postoperative complications. However, we were very aggressive in obtaining biopsies in our patients and enrolled many patients older than 70 yr of age (n = 46). Subjects referred to our institution might represent a subset of patients with IPF with more aggressive disease. This seems unlikely given that our study population was similar to that of previous studies and the survival was also comparable to recent series (5, 33, 34). Also, only 158 of the 238 patients underwent assessment of both lung mechanics and exercise response from which the complete model was derived, and it is possible that this subset of patients on whom the complete scoring system was developed was different from the larger patient population. However, several models run with indicators of lung mechanics and exercise testing demonstrated that their absence was not indicative of increased risk of death (data not shown). In addition, in constructing the model there were several patients who were highly influential in the analysis. Because our goal was to develop a score for the general population of persons with IPF, and we did not want a few "outliers" to drive the model. We chose to focus on the middle of the distribution where most of the patients are, rather than the ends. We used a bootstrapping approach to validate our final model (data not shown). Although it is clear that the model performs better for the patients who were not highly influential, when these "outliers" are included in the model, it still performs well. Also, we performed a sensitivity analyses to look at the effect of censoring transplanted patients and patients who did not die of ILD (data not shown). The final model was run assuming that all of the transplanted patients died at the time of transplant. Because this model is not nested within the model assuming that the transplanted patients were censored, these models could not be compared directly. However, the likelihood ratio test and the Wald tests for the individual variables in the model remained significant when the transplanted patients and the patients who did not die of ILD were treated as if they had died at the time of transplant or had died of IPF. In fact, the model that treated the transplanted patients as having died had p values for all variables that was the same or lower than our original model. Similar results were found for the sensitivity analysis treating the subset of patients who did not die of ILD. In fact, the group of patients who died of other causes than ILD had a higher proportion of current smokers and lived longer than those patients who died of ILD. Therefore, by censoring this group we were being conservative. This group includes patients who lived long enough to die of causes other than ILD. Importantly, this model must be validated in another cohort of patients with IPF.

In summary, we have provided data derived from a large prospectively enrolled cohort showing which clinical, radiologic, and physiologic features of IPF influence survival. This analysis derived a complete CRP model that can be used to estimate the survival time in a patient with IPF. The model includes the following parameters: age, smoking history; clubbing; extent of profusion of interstitial opacities, and presence or absence of pulmonary hypertension on the chest radiograph; % predicted TLC; and PaO2 at the end of maximal exercise. This complete model was superior to a second abbreviated model and to our originally reported CRP in predicting survival in IPF. Nevertheless, the abbreviated grading system would likely have more general applicability since most physicians do not have access to measurements of cardiopulmonary exercise testing.

Applying these models, clinicians will be in a better position to provide prognostic information to patients with IPF and to improve the selection of the most appropriate patients for lung transplantation or other standard or novel therapeutic interventions. Importantly, we have identified several factors that influence survival that must be taken into account for use in any future therapeutic trial.


    Footnotes

Correspondence and requests for reprints should be addressed to Talmadge E. King, Jr., M.D., San Francisco General Hospital, Room 5H22, 1001 Potrero Avenue, San Francisco, CA 94110. E-mail: tking{at}medsfgh.ucsf.edu

(Received in original form March 24, 2000 and in revised form May 23, 2001).

Acknowledgments: The writers thank Drs. L.C. Watters, T.L. Dunn, A. Shen, and R.L. Mortenson for their role in enrolling patients; Alma (Dolly) Kervitsky, S. Arlene Niccoli, Martin Wallace, Trudy McDermott, and Janet Henson for their technical assistance; Drs. Thomas V. Colby, James A. Waldron, Jr., Andrew Flint, and William Thurlbeck; Becki Bucher Bartelson for her assistance with the data analysis; William Kastner and David Ikle for the design and maintenance of the computerized data for the ILD study; the referring physicians; and a special thanks to the patients for allowing the investigators to participate in their care.

Supported by a Specialized Center of Research (SCOR) Grant No. HL-27353 from the National Heart, Lung and Blood Institute.


    References
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

1. Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease [see comments]. Lancet 1998; 351: 24-27 [Medline].

2. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 1980; 35: 593-599 [Abstract/Free Full Text].

3. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35: 171-180 [Abstract/Free Full Text].

4. Tukiainen P, Taskinen E, Holsti P, Korhola O, Valle M. Prognosis of cryptogenic fibrosing alveolitis. Thorax 1983; 38: 349-355 [Abstract/Free Full Text].

5. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199-203 .

6. Katzenstein ALA, Myers JL. Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157: 1301-1315 [Free Full Text].

7. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-664.

8. Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE, Cherniack RM. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986; 133: 97-103 [Medline].

9. Watters LC, Schwarz MI, Cherniack RM, Waldron JA, Dunn TL, Stanford RE, King Jr TE. Idiopathic pulmonary fibrosis: pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis 1987; 135:696-704.

10. Dubois AB, Botelho SY, Comroe JH Jr.. A new method for measuring airway resistance in man using a body plethysmograph: values in normal subjects and in patients with respiratory disease. J Clin Invest 1956; 35: 327-335 .

11. Goldman HI, Becklake MR. Respiratory function tests. Normal value at medium altitude and the prediction of normal results. Am Rev Tuberc 1959; 79: 457-467 . [Medline]

12. Morris JF, Koski A, Johnson LC. Spirometric standard for healthy nonsmoking adult. Am Rev Respir Dis 1971; 103: 57-67 [Medline].

13. Ogilvie C, Foster R, Blakemore W, Morgan J. A standardized breathholding technique for the clinical measurement of diffusing capacity of the lung for carbon monoxide. J Clin Invest 1957; 36: 1-17 .

14. Crapo RO, Morris AH. Standardized single breath values for carbon monoxide diffusing capacity. Am Rev Respir Dis 1981; 123: 185-189 [Medline].

15. Gibson GJ, Pride NB. Lung distensibility. The static pressure-volume curve of the lungs and its use in clinical assessment. Br J Dis Chest 1976; 70: 143-183 [Medline].

16. Thompson MJ, Colebatch HJ. Decreased pulmonary distensibility in fibrosing alveolitis and its relation to decreased lung volume. Thorax 1989; 44: 725-731 [Abstract/Free Full Text].

17. Cherniack RM, Colby TV, Flint A, Thurlbeck WM, Waldron JA Jr, Ackerson L, Schwarz MI, King Jr TE. Correlation of structure and function in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995;151:1180- 1188.

18. Riley RL, Cournand A. Ideal alveolar air and the analysis of ventilation-perfusion relationships in the lungs. J Appl Physiol 1949; 1: 825-847 [Free Full Text].

19. Jones NL, Campbell EJM. Clinical exercise testing. Philadelphia: W. B. Saunders Co; 1982, p 249.

20. Cherniack RM, Colby TV, Flint A, Thurlbeck WM, Waldron JA, King Jr TE, and BAL Cooperative Group Steering Committee. Quantitative assessment of lung pathology in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1991;144:892-900.

21. Hyde DM, King TE Jr, McDermott T, Waldron Fr JA, Colby TV, Thurlbeck WM, Flint A, Ackerson L, Cherniack RM. Idiopathic pulmonary fibrosis: the quantitative assessment of lung pathology. Comparison of a semiquantitative versus a morphometric histopathologic scoring system. Am Rev Respir Dis 1992;146:1042-1047.

22. Collett D. Modelling survival data in medical research. London: Chapman & Hall; 1994.

23. Pettitt AN, Bin Daud I. Case-weighted measures of influence for proportional hazards regression. Appl Stat 1989;38:51-67.

24. Akaike H. A new look at the statistical model identification. IEEE Trans Auto Control 1974;AC-19:716-723.

25. King Jr TE, Schwarz MI, Brown K, Tooze J, Colby TV, Waldron JA Jr, Flint A, Thurlbeck W, Cherniack RM. The relation between histopathological features and mortality in a prospective study of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (in press)

26. Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL, Dayton CS, Burmeister LF, Hunninghake GW. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149: 450-454 [Abstract].

27. Carrington CB, Gaensler EA, Coutu RE, Fitzgerald MX, Gupta RG. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298: 801-809 [Abstract].

28. Johnston IDA, Prescott RJ, Chalmers JC, Rudd RM. for the Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax 1997; 52: 38-44 [Abstract/Free Full Text].

29. Baumgartner KB, Samet J, Stidley CA, Colby TV, Waldron JA. the Collaborating Centers. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997; 155: 242-248 [Abstract].

30. Hanley ME, King TE Jr,, Schwarz MI, Watters LC, Shen AS, Cherniack RM. The impact of smoking on mechanical properties of the lungs in idiopathic pulmonary fibrosis and sarcoidosis. Am Rev Respir Dis 1991; 144: 1102-1106 [Medline].

31. Nakamura Y, Romberger DJ, Tate L, Ertl RF, Kawamoto M, Adachi Y, Mio T, Sisson JH, Spurzem JR, Rennard SI. Cigarette smoke inhibits lung fibroblast proliferation and chemotaxis. Am J Respir Crit Care Med 1995; 151: 1497-1503 [Abstract].

32. Terriff BA, Kwan SY, Chan-Yeung MM, Mueller NL. Fibrosing alveolitis: chest radiology and CT as predictors of clinical and functional impairment at follow-up in 26 patients. Radiology 1992; 184: 445-449 [Abstract/Free Full Text].

33. Daniil ZD, Gilchrist FC, Nicholson AG, Hansell DM, Harris J, Colby TV, du Bois RM. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999; 160: 899-905 [Abstract/Free Full Text].

34. Nagai S, Kitaichi M, Itoh H, Nishimura K, Izumi T, Colby TV. Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. Eur Respir J 1998; 12: 1010-1019 [Abstract].





This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
S.-I. Cha, S. D. Groshong, S. K. Frankel, B. L. Edelman, G. P. Cosgrove, J. L. Terry-Powers, L. K. Remigio, D. Curran-Everett, K. K. Brown, C. D. Cool, et al.
Compartmentalized Expression of c-FLIP in Lung Tissues of Patients with Idiopathic Pulmonary Fibrosis
Am. J. Respir. Cell Mol. Biol., February 1, 2010; 42(2): 140 - 148.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
V. Cottin, J. Le Pavec, G. Prevot, H. Mal, M. Humbert, G. Simonneau, J-F. Cordier, and GERM"O"P
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome
Eur. Respir. J., January 1, 2010; 35(1): 105 - 111.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
E. R. F. Perez, C. E. Daniels, D. R. Schroeder, J. St. Sauver, T. E. Hartman, B. J. Bartholmai, E. S. Yi, and J. H. Ryu
Incidence, Prevalence, and Clinical Course of Idiopathic Pulmonary Fibrosis: A Population-Based Study
Chest, January 1, 2010; 137(1): 129 - 137.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
J M Harris, I D A Johnston, R Rudd, A J N. Taylor, and P Cullinan
Cryptogenic fibrosing alveolitis and lung cancer: the BTS study
Thorax, January 1, 2010; 65(1): 70 - 76.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. J. Swigris, J. Swick, F. S. Wamboldt, D. Sprunger, R. du Bois, A. Fischer, G. P. Cosgrove, S. K. Frankel, E. R. Fernandez-Perez, D. Kervitsky, et al.
Heart Rate Recovery After 6-Min Walk Test Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis
Chest, September 1, 2009; 136(3): 841 - 848.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
D. J. Lederer, P. L. Enright, S. M. Kawut, E. A. Hoffman, G. Hunninghake, E. J. R. van Beek, J. H. M. Austin, R. Jiang, G. S. Lovasi, and R. G. Barr
Cigarette Smoking Is Associated with Subclinical Parenchymal Lung Disease: The Multi-Ethnic Study of Atherosclerosis (MESA)-Lung Study
Am. J. Respir. Crit. Care Med., September 1, 2009; 180(5): 407 - 414.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. Mejia, G. Carrillo, J. Rojas-Serrano, A. Estrada, T. Suarez, D. Alonso, E. Barrientos, M. Gaxiola, C. Navarro, and M. Selman
Idiopathic Pulmonary Fibrosis and Emphysema: Decreased Survival Associated With Severe Pulmonary Arterial Hypertension
Chest, July 1, 2009; 136(1): 10 - 15.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
B. W. Kinder, K. K. Brown, F. X. McCormack, J. H. Ix, A. Kervitsky, M. I. Schwarz, and T. E. King Jr
Serum Surfactant Protein-A Is a Strong Predictor of Early Mortality in Idiopathic Pulmonary Fibrosis
Chest, June 1, 2009; 135(6): 1557 - 1563.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
A. Prasse, C. Probst, E. Bargagli, G. Zissel, G. B. Toews, K. R. Flaherty, M. Olschewski, P. Rottoli, and J. Muller-Quernheim
Serum CC-Chemokine Ligand 18 Concentration Predicts Outcome in Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., April 15, 2009; 179(8): 717 - 723.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
A. Moeller, S. E. Gilpin, K. Ask, G. Cox, D. Cook, J. Gauldie, P. J. Margetts, L. Farkas, J. Dobranowski, C. Boylan, et al.
Circulating Fibrocytes Are an Indicator of Poor Prognosis in Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., April 1, 2009; 179(7): 588 - 594.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
C. D. Fell, L. X. Liu, C. Motika, E. A. Kazerooni, B. H. Gross, W. D. Travis, T. V. Colby, S. Murray, G. B. Toews, F. J. Martinez, et al.
The Prognostic Value of Cardiopulmonary Exercise Testing in Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., March 1, 2009; 179(5): 402 - 407.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
A. Ferreira, C. Garvey, G. L. Connors, L. Hilling, J. Rigler, S. Farrell, C. Cayou, C. Shariat, and H. R. Collard
Pulmonary Rehabilitation in Interstitial Lung Disease: Benefits and Predictors of Response
Chest, February 1, 2009; 135(2): 442 - 447.
[Abstract] [Full Text] [PDF]


Home page
ACCP Pulmonary Med Brd RevHome page
H. D. Tazelaar
Pathology of Diffuse and Neoplastic Disease
ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 501 - 512.
[Full Text] [PDF]


Home page
ACCP Pulmonary Med Brd RevHome page
J. P. Lynch III
Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonia/Fibrosis, and Sarcoidosis
ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 635 - 686.
[Full Text] [PDF]


Home page
RadiologyHome page
A. Devaraj, A. U. Wells, M. G. Meister, T. J. Corte, and D. M. Hansell
The Effect of Diffuse Pulmonary Fibrosis on the Reliability of CT Signs of Pulmonary Hypertension
Radiology, December 1, 2008; 249(3): 1042 - 1049.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
A U Wells, N Hirani, and on behalf of the BTS Interstitial Lung Disease Gui
Interstitial lung disease guideline
Thorax, September 1, 2008; 63(Suppl_5): v1 - v58.
[Full Text] [PDF]


Home page
Eur Respir JHome page
J. Behr and J. H. Ryu
Pulmonary hypertension in interstitial lung disease
Eur. Respir. J., June 1, 2008; 31(6): 1357 - 1367.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
C. Strange and J. R. Seibold
Scleroderma Lung Disease: "If You Don't Know Where You Are Going, Any Road Will Take You There"
Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1178 - 1179.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
N. S. L. Goh, S. R. Desai, S. Veeraraghavan, D. M. Hansell, S. J. Copley, T. M. Maher, T. J. Corte, C. R. Sander, J. Ratoff, A. Devaraj, et al.
Interstitial Lung Disease in Systemic Sclerosis: A Simple Staging System
Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1248 - 1254.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
G. Trujillo, E. C. O'Connor, S. L. Kunkel, and C. M. Hogaboam
A Novel Mechanism for CCR4 in the Regulation of Macrophage Activation in Bleomycin-Induced Pulmonary Fibrosis
Am. J. Pathol., May 1, 2008; 172(5): 1209 - 1221.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
C. E. Papadopoulos, G. Pitsiou, T. D. Karamitsos, H. I. Karvounis, T. Kontakiotis, G. Giannakoulas, G. K. Efthimiadis, P. Argyropoulou, G. E. Parharidis, and D. Bouros
Left ventricular diastolic dysfunction in idiopathic pulmonary fibrosis: a tissue Doppler echocardiographic study
Eur. Respir. J., April 1, 2008; 31(4): 701 - 706.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
T J Williams and J W Wilson
Challenges in pulmonary fibrosis: 7 {middle dot} Novel therapies and lung transplantation
Thorax, March 1, 2008; 63(3): 277 - 284.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
K. M. Antoniou, D. M. Hansell, M. B. Rubens, K. Marten, S. R. Desai, N. M. Siafakas, A. G. Nicholson, R. M. du Bois, and A. U. Wells
Idiopathic Pulmonary Fibrosis: Outcome in Relation to Smoking Status
Am. J. Respir. Crit. Care Med., January 15, 2008; 177(2): 190 - 194.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
T. E. King Jr., J. Behr, K. K. Brown, R. M. du Bois, L. Lancaster, J. A. de Andrade, G. Stahler, I. Leconte, S. Roux, and G. Raghu
BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 75 - 81.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
B. W. Kinder, K. K. Brown, M. I. Schwarz, J. H. Ix, A. Kervitsky, and T. E. King Jr
Baseline BAL Neutrophilia Predicts Early Mortality in Idiopathic Pulmonary Fibrosis
Chest, January 1, 2008; 133(1): 226 - 232.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. R. Hemnes, A. Zaiman, and H. C. Champion
PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation
Am J Physiol Lung Cell Mol Physiol, January 1, 2008; 294(1): L24 - L33.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
A. F. Shorr, J. L. Wainright, C. S. Cors, C. J. Lettieri, and S. D. Nathan
Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant
Eur. Respir. J., October 1, 2007; 30(4): 715 - 721.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
A. U Wells, A. G Nicholson, and D. M Hansell
Challenges in pulmonary fibrosis {middle dot} 4: Smoking-induced diffuse interstitial lung diseases
Thorax, October 1, 2007; 62(10): 904 - 910.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
I. O. Rosas, P. Ren, N. A. Avila, C. K. Chow, T. J. Franks, W. D. Travis, J. P. McCoy Jr., R. M. May, H.-P. Wu, D. M. Nguyen, et al.
Early Interstitial Lung Disease in Familial Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., October 1, 2007; 176(7): 698 - 705.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
N. M. Patel, D. J. Lederer, A. C. Borczuk, and S. M. Kawut
Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis
Chest, September 1, 2007; 132(3): 998 - 1006.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
G. W. Hunninghake and M. I. Schwarz
State of the Art. Does Current Knowledge Explain the Pathogenesis of Idiopathic Pulmonary Fibrosis?: A Perspective
Proceedings of the ATS, August 15, 2007; 4(5): 449 - 452.
[Abstract] [Full Text] [PDF]


Home page
ERRHome page
R. M. du Bois
Blocking endothelin: breaking new ground
Eur. Respir. Rev., August 1, 2007; 16(102): 24 - 29.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
D. Kass, R. S. Bridges, A. Borczuk, and S. Greenberg
Methionine Aminopeptidase-2 as a Selective Target of Myofibroblasts in Pulmonary Fibrosis
Am. J. Respir. Cell Mol. Biol., August 1, 2007; 37(2): 193 - 201.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
S. D. Nathan, P. W. Noble, and R. M. Tuder
Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension: Connecting the Dots
Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 875 - 880.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. Alakhras, P. A. Decker, H. F. Nadrous, M. Collazo-Clavell, and J. H. Ryu
Body Mass Index and Mortality in Patients With Idiopathic Pulmonary Fibrosis
Chest, May 1, 2007; 131(5): 1448 - 1453.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. D. Fell and F. J. Martinez
The Impact of Pulmonary Arterial Hypertension on Idiopathic Pulmonary Fibrosis
Chest, March 1, 2007; 131(3): 641 - 643.
[Full Text] [PDF]


Home page
ChestHome page
S. D. Nathan, O. A. Shlobin, S. Ahmad, S. Urbanek, and S. D. Barnett
Pulmonary Hypertension and Pulmonary Function Testing in Idiopathic Pulmonary Fibrosis
Chest, March 1, 2007; 131(3): 657 - 663.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. Portnoy, K. L. Veraldi, M. I. Schwarz, C. D. Cool, D. Curran-Everett, R. M. Cherniack, T. E. King Jr, and K. K. Brown
Respiratory Bronchiolitis-Interstitial Lung Disease: Long-term Outcome
Chest, March 1, 2007; 131(3): 664 - 671.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
K. Hamada, S. Nagai, S. Tanaka, T. Handa, M. Shigematsu, T. Nagao, M. Mishima, M. Kitaichi, and T. Izumi
Significance of Pulmonary Arterial Pressure and Diffusion Capacity of the Lung as Prognosticator in Patients With Idiopathic Pulmonary Fibrosis
Chest, March 1, 2007; 131(3): 650 - 656.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
J. H. Ryu, M. J. Krowka, K. L. Swanson, P. A. Pellikka, and M. D. McGoon
Pulmonary Hypertension in Patients With Interstitial Lung Diseases
Mayo Clin. Proc., March 1, 2007; 82(3): 342 - 350.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
H. H. Leuchte, M. El Nounou, J. C. Tuerpe, B. Hartmann, R. A. Baumgartner, M. Vogeser, O. Muehling, and J. Behr
N-terminal Pro-Brain Natriuretic Peptide and Renal Insufficiency as Predictors of Mortality in Pulmonary Hypertension
Chest, February 1, 2007; 131(2): 402 - 409.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
S. Dal Corso, S. R. Duarte, J. A. Neder, C. Malaguti, M. B. de Fuccio, C. A. de Castro Pereira, and L. E. Nery
A step test to assess exercise-related oxygen desaturation in interstitial lung disease
Eur. Respir. J., February 1, 2007; 29(2): 330 - 336.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
P. Palange, S. A. Ward, K-H. Carlsen, R. Casaburi, C. G. Gallagher, R. Gosselink, D. E. O'Donnell, L. Puente-Maestu, A. M. Schols, S. Singh, et al.
Recommendations on the use of exercise testing in clinical practice
Eur. Respir. J., January 1, 2007; 29(1): 185 - 209.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
W. O. Villalba, P. D. Sampaio-Barros, M. C. Pereira, E. M. F. P. Cerqueira, C. A. Leme Jr, J. F. Marques-Neto, and I. A. Paschoal
Six-Minute Walk Test for the Evaluation of Pulmonary Disease Severity in Scleroderma Patients
Chest, January 1, 2007; 131(1): 217 - 222.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
A U Wells, D M Hansell, and A G Nicholson
What is this thing called CFA?
Thorax, January 1, 2007; 62(1): 3 - 4.
[Full Text] [PDF]


Home page
ThoraxHome page
R. M Rudd, R. J Prescott, J C Chalmers, I. D A Johnston, and for the Fibrosing Alveolitis Subcommittee of the R
British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival
Thorax, January 1, 2007; 62(1): 62 - 66.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
L Tiitto, R Bloigu, U Heiskanen, P Paakko, V L Kinnula, and R Kaarteenaho-Wiik
Relationship between histopathological features and the course of idiopathic pulmonary fibrosis/usual interstitial pneumonia
Thorax, December 1, 2006; 61(12): 1091 - 1095.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
M. Yamamoto, M. Otani, and M. Otsuki
A new model of chronic pancreatitis in rats.
Am J Physiol Gastrointest Liver Physiol, October 1, 2006; 291(4): G700 - G708.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
G. Raghu, D. Weycker, J. Edelsberg, W. Z. Bradford, and G. Oster
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., October 1, 2006; 174(7): 810 - 816.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
K. R. Flaherty, A.-C. Andrei, S. Murray, C. Fraley, T. V. Colby, W. D. Travis, V. Lama, E. A. Kazerooni, B. H. Gross, G. B. Toews, et al.
Idiopathic Pulmonary Fibrosis: Prognostic Value of Changes in Physiology and Six-Minute-Walk Test
Am. J. Respir. Crit. Care Med., October 1, 2006; 174(7): 803 - 809.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
D. J. Lederer, S. M. Arcasoy, J. S. Wilt, F. D'Ovidio, J. R. Sonett, and S. M. Kawut
Six-Minute-Walk Distance Predicts Waiting List Survival in Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., September 15, 2006; 174(6): 659 - 664.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
C. D. Cool, S. D. Groshong, P. R. Rai, P. M. Henson, J. S. Stewart, and K. K. Brown
Fibroblast Foci Are Not Discrete Sites of Lung Injury or Repair: The Fibroblast Reticulum
Am. J. Respir. Crit. Care Med., September 15, 2006; 174(6): 654 - 658.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
K. M. Antoniou, A. G. Nicholson, M. Dimadi, K. Malagari, P. Latsi, A. Rapti, N. Tzanakis, R. Trigidou, V. Polychronopoulos, and D. Bouros
Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis
Eur. Respir. J., September 1, 2006; 28(3): 496 - 504.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
T. E. King Jr and M. Selman
Introduction
Proceedings of the ATS, June 1, 2006; 3(4): 283 - 284.
[Full Text] [PDF]


Home page
ChestHome page
Y. S. Wasfi, C. S. Rose, J. R. Murphy, L. J. Silveira, J. C. Grutters, Y. Inoue, M. A. Judson, and L. A. Maier
A New Tool To Assess Sarcoidosis Severity
Chest, May 1, 2006; 129(5): 1234 - 1245.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
H. H. Leuchte, R. A. Baumgartner, M. E. Nounou, M. Vogeser, C. Neurohr, M. Trautnitz, and J. Behr
Brain Natriuretic Peptide Is a Prognostic Parameter in Chronic Lung Disease
Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 744 - 750.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. J. Lettieri, S. D. Nathan, S. D. Barnett, S. Ahmad, and A. F. Shorr
Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis
Chest, March 1, 2006; 129(3): 746 - 752.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
G. Raghu, S. T.-Y. Yang, C. Spada, J. Hayes, and C. A. Pellegrini
Sole Treatment of Acid Gastroesophageal Reflux in Idiopathic Pulmonary Fibrosis: A Case Series
Chest, March 1, 2006; 129(3): 794 - 800.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
F. J. Martinez
Idiopathic Interstitial Pneumonias: Usual Interstitial Pneumonia versus Nonspecific Interstitial Pneumonia.
Proceedings of the ATS, January 1, 2006; 3(1): 81 - 95.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
D. S. Kim, H. R. Collard, and T. E. King Jr.
Classification and natural history of the idiopathic interstitial pneumonias.
Proceedings of the ATS, January 1, 2006; 3(4): 285 - 292.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
F. J. Martinez and K. Flaherty
Pulmonary function testing in idiopathic interstitial pneumonias.
Proceedings of the ATS, January 1, 2006; 3(4): 315 - 321.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
N. Walter, H. R. Collard, and T. E. King Jr.
Current perspectives on the treatment of idiopathic pulmonary fibrosis.
Proceedings of the ATS, January 1, 2006; 3(4): 330 - 338.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
R. Pellegrino, G. Viegi, V. Brusasco, R. O. Crapo, F. Burgos, R. Casaburi, A. Coates, C. P. M. van der Grinten, P. Gustafsson, J. Hankinson, et al.
Interpretative strategies for lung function tests
Eur. Respir. J., November 1, 2005; 26(5): 948 - 968.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. P. Steele, M. C. Speer, J. E. Loyd, K. K. Brown, A. Herron, S. H. Slifer, L. H. Burch, M. M. Wahidi, J. A. Phillips III, T. A. Sporn, et al.
Clinical and Pathologic Features of Familial Interstitial Pneumonia
Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1146 - 1152.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
S. D. Nathan
Therapeutic Intervention: Assessing the Role of the International Consensus Guidelines
Chest, November 1, 2005; 128(5_suppl_1): 533S - 539S.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
V. Cottin, H. Nunes, P-Y. Brillet, P. Delaval, G. Devouassoux, I. Tillie-Leblond, D. Israel-Biet, I. Court-Fortune, D. Valeyre, J-F. Cordier, et al.
Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity
Eur. Respir. J., October 1, 2005; 26(4): 586 - 593.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. Strange
Treatment for Secondary Pulmonary Hypertension
Chest, October 1, 2005; 128(4): 1897 - 1898.
[Full Text] [PDF]


Home page
ChestHome page
L. Tiitto, U. Heiskanen, R. Bloigu, P. Paakko, V. Kinnula, and R. Kaarteenaho-Wiik
Thoracoscopic Lung Biopsy Is a Safe Procedure in Diagnosing Usual Interstitial Pneumonia
Chest, October 1, 2005; 128(4): 2375 - 2380.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
H. F. Nadrous, P. A. Pellikka, M. J. Krowka, K. L. Swanson, N. Chaowalit, P. A. Decker, and J. H. Ryu
Pulmonary Hypertension in Patients With Idiopathic Pulmonary Fibrosis
Chest, October 1, 2005; 128(4): 2393 - 2399.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
M. A Pacanowski and G. W Amsden
Interferon Gamma-1b in the Treatment of Idiopathic Pulmonary Fibrosis
Ann. Pharmacother., October 1, 2005; 39(10): 1678 - 1686.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
H. Date, Y. Tanimoto, K. Goto, I. Yamadori, M. Aoe, Y. Sano, and N. Shimizu
A New Treatment Strategy for Advanced Idiopathic Interstitial Pneumonia*: Living-Donor Lobar Lung Transplantation
Chest, September 1, 2005; 128(3): 1364 - 1370.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
T. E. King Jr.
Clinical Advances in the Diagnosis and Therapy of the Interstitial Lung Diseases
Am. J. Respir. Crit. Care Med., August 1, 2005; 172(3): 268 - 279.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
A. Azuma, T. Nukiwa, E. Tsuboi, M. Suga, S. Abe, K. Nakata, Y. Taguchi, S. Nagai, H. Itoh, M. Ohi, et al.
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., May 1, 2005; 171(9): 1040 - 1047.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
J J Egan, F J Martinez, A U Wells, and T Williams
Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification
Thorax, April 1, 2005; 60(4): 270 - 273.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
I. Ito, S. Nagai, M. Kitaichi, A. G. Nicholson, T. Johkoh, S. Noma, D. S. Kim, T. Handa, T. Izumi, and M. Mishima
Pulmonary Manifestations of Primary Sjogren's Syndrome: A Clinical, Radiologic, and Pathologic Study
Am. J. Respir. Crit. Care Med., March 15, 2005; 171(6): 632 - 638.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
Y. Jegal, D. S. Kim, T. S. Shim, C.-M. Lim, S. Do Lee, Y. Koh, W. S. Kim, W. D. Kim, J. S. Lee, W. D. Travis, et al.
Physiology Is a Stronger Predictor of Survival than Pathology in Fibrotic Interstitial Pneumonia
Am. J. Respir. Crit. Care Med., March 15, 2005; 171(6): 639 - 644.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
S. D. Nathan
Lung Transplantation: Disease-Specific Considerations for Referral
Chest, March 1, 2005; 127(3): 1006 - 1016.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
J. M. Pilewski, L. Liu, A. C. Henry, A. V. Knauer, and C. A. Feghali-Bostwick
Insulin-Like Growth Factor Binding Proteins 3 and 5 Are Overexpressed in Idiopathic Pulmonary Fibrosis and Contribute to Extracellular Matrix Deposition
Am. J. Pathol., February 1, 2005; 166(2): 399 - 407.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
T. S. Hallstrand, L. J. Boitano, W. C. Johnson, C. A. Spada, J. G. Hayes, and G. Raghu
The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis
Eur. Respir. J., January 1, 2005; 25(1): 96 - 103.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. J. Swigris, W. G. Kuschner, J. L. Kelsey, and M. K. Gould
Idiopathic Pulmonary Fibrosis: Challenges and Opportunities for the Clinician and Investigator
Chest, January 1, 2005; 127(1): 275 - 283.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
H. F. Nadrous, J. L. Myers, P. A. Decker, and J. H. Ryu
Idiopathic Pulmonary Fibrosis in Patients Younger Than 50 Years
Mayo Clin. Proc., January 1, 2005; 80(1): 37 - 40.
[Abstract] [PDF]


Home page
ChestHome page
M. Bonay, C. Bancal, D. de Zuttere, F. Arnoult, G. Saumon, and F. Camus
Normal Pulmonary Capillary Blood Volume in Patients With Chronic Infiltrative Lung Disease and High Pulmonary Artery Pressure
Chest, November 1, 2004; 126(5): 1460 - 1466.
[Abstract] [Full Text] [PDF]


Home page
ImagingHome page
N J Screaton and T Koh
Emphysema and smoking-related lung diseases
Imaging, October 1, 2004; 16(1): 50 - 60.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
N. S. Hill
Brain Natriuretic Peptide: Is It Helpful in Detecting Pulmonary Hypertension in Fibrotic Lung Disease?
Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 352 - 353.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
H. H. Leuchte, C. Neurohr, R. Baumgartner, M. Holzapfel, W. Giehrl, M. Vogeser, and J. Behr
Brain Natriuretic Peptide and Exercise Capacity in Lung Fibrosis and Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 360 - 365.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
G. P. Cosgrove, K. K. Brown, W. P. Schiemann, A. E. Serls, J. E. Parr, M. W. Geraci, M. I. Schwarz, C. D. Cool, and G. S. Worthen
Pigment Epithelium-derived Factor in Idiopathic Pulmonary Fibrosis: A Role in Aberrant Angiogenesis
Am. J. Respir. Crit. Care Med., August 1, 2004; 170(3): 242 - 251.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
G. Raghu, K. K. Brown, W. Z. Bradford, K. Starko, P. W. Noble, D. A. Schwartz, T. E. King Jr., and the Idiopathic Pulmonary Fibrosis Study Group
A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis
N. Engl. J. Med., January 8, 2004; 350(2): 125 - 133.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
V. N. Lama, K. R. Flaherty, G. B. Toews, T. V. Colby, W. D. Travis, Q. Long, S. Murray, E. A. Kazerooni, B. H. Gross, J. P. Lynch III, et al.
Prognostic Value of Desaturation during a 6-Minute Walk Test in Idiopathic Interstitial Pneumonia
Am. J. Respir. Crit. Care Med., November 1, 2003; 168(9): 1084 - 1090.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. Selman
The Spectrum of Smoking-Related Interstitial Lung Disorders: The Never-Ending Story of Smoke and Disease
Chest, October 1, 2003; 124(4): 1185 - 1187.
[Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. Cisneros-Lira, M. Gaxiola, C. Ramos, M. Selman, and A. Pardo
Cigarette smoke exposure potentiates bleomycin-induced lung fibrosis in guinea pigs
Am J Physiol Lung Cell Mol Physiol, October 1, 2003; 285(4): L949 - L956.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
N. Kaminski, J. A. Belperio, P. B. Bitterman, L. Chen, S. W. Chensue, A. M.K. Choi, S. Dacic, J. H. Dauber, R. M. du Bois, J. J. Enghild, et al.
Idiopathic Pulmonary Fibrosis
Am. J. Respir. Cell Mol. Biol., September 1, 2003; 29(3): S1 - 105.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
H. R. Collard, T. E. King Jr., B. B. Bartelson, J. S. Vourlekis, M. I. Schwarz, and K. K. Brown
Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., September 1, 2003; 168(5): 538 - 542.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
K. R. Flaherty, J. A. Mumford, S. Murray, E. A. Kazerooni, B. H. Gross, T. V. Colby, W. D. Travis, A. Flint, G. B. Toews, J. P. Lynch III, et al.
Prognostic Implications of Physiologic and Radiographic Changes in Idiopathic Interstitial Pneumonia
Am. J. Respir. Crit. Care Med., September 1, 2003; 168(5): 543 - 548.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
P. I. Latsi, R. M. du Bois, A. G. Nicholson, T. V. Colby, D. Bisirtzoglou, A. Nikolakopoulou, S. Veeraraghavan, D. M. Hansell, and A. U. Wells
Fibrotic Idiopathic Interstitial Pneumonia: The Prognostic Value of Longitudinal Functional Trends
Am. J. Respir. Crit. Care Med., September 1, 2003; 168(5): 531 - 537.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
G. Thabut, H. Mal, Y. Castier, O. Groussard, O. Brugiere, R. Marrash-Chahla, G. Leseche, and M. Fournier
Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis
J. Thorac. Cardiovasc. Surg., August 1, 2003; 126(2): 469 - 475.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
F. Laghi and M. J. Tobin
Disorders of the Respiratory Muscles
Am. J. Respir. Crit. Care Med., July 1, 2003; 168(1): 10 - 48.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. Chilosi, V. Poletti, A. Zamo, M. Lestani, L. Montagna, P. Piccoli, S. Pedron, M. Bertaso, A. Scarpa, B. Murer, et al.
Aberrant Wnt/{beta}-Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis
Am. J. Pathol., May 1, 2003; 162(5): 1495 - 1502.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
A. U. Wells, S. R. Desai, M. B. Rubens, N. S. L. Goh, D. Cramer, A. G. Nicholson, T. V. Colby, R. M. du Bois, and D. M. Hansell
Idiopathic Pulmonary Fibrosis: A Composite Physiologic Index Derived from Disease Extent Observed by Computed Tomography
Am. J. Respir. Crit. Care Med., April 1, 2003; 167(7): 962 - 969.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
N. Mayer-Hamblett, M. Rosenfeld, J. Emerson, C. H. Goss, and M. L. Aitken
Developing Cystic Fibrosis Lung Transplant Referral Criteria Using Predictors of 2-Year Mortality
Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): 1550 - 1555.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KING, T. E.
Right arrow Articles by CHERNIACK, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KING, T. E., JR.
Right arrow Articles by CHERNIACK, R. M.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2001 American Thoracic Society